Metraipolis › archive › dc_22fe2ba73722
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management — Europe PMC PMID:42309786
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42309786
- DOI
- 10.1111/1759-7714.70328
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T01:34:03.556Z
- SHA-256 of the archived text
a86ab10ae744cdea69597c70d954bb71b5e5546e9db78e703fcb569b78c6394c- Stable URL of this page
https://metraipolis.com/documento/dc_22fe2ba73722
How to cite
Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management — Europe PMC PMID:42309786 — Europe PMC (en), https://europepmc.org/article/MED/42309786 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_22fe2ba73722 (Metraipolis archive dc_22fe2ba73722, sha256 a86ab10ae744cdea69597c70d954bb71b5e5546e9db78e703fcb569b78c6394c)
BibTeX
@misc{dc22fe2ba73722,
title = {Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management — Europe PMC PMID:42309786},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42309786},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_22fe2ba73722; sha256 a86ab10ae744cdea69597c70d954bb71b5e5546e9db78e703fcb569b78c6394c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42309786. Agents can read the archived copy with the MCP tool read_document.